Finland· FI-REL-REL62179
Pamorelin
A triptorelin product containing triptorelin embonate, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Triptorelin is registered in 11 of 19 countries.
Countries holding a registration under ATC L02AE04 (triptorelin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Triptorelin · ATC L02AE04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of triptorelin costs, country by country.
Normalised to the WHO defined daily dose (0.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Triptorelin · price per daily dose (0.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.91
The record
At a glance
Fimea (Finland)- Active substance
- Triptorelin embonate
- Manufacturer
- Abacus Medicine A/S
- Country
- Finland (FI)
- ATC code
- L02AE04
- ATC class
- Triptorelin
- Defined daily dose
- 0.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa48115222.5 mg + 2 mlEUR 622.84
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
321 interactions on record for triptorelin.
Graded by severity as the source publishes them — 69 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Triptorelin · interactions on record
321 records
- 69 severe
- 249 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Triptorelin in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandDecapeptyl 6-month 22.5 mg Powder and solvent for prolonged-release suspension for injectionBModesto B.V.
- BelgiumDecapeptyl Sustained Release 11.25 mgIpsen
- CzechiaDIPHERELINE S.R.IPSEN PHARMA S.A.S., Paříž
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- France · Bedelix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f607cf28-9200-4497-812f-993d80fb8405 GET /v1/drugs/f607cf28-9200-4497-812f-993d80fb8405?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.134",
"form": "injektiokuiva-aine ja liuotin, depotsuspensiota varten",
"route": "Lihakseen",
"ddd_unit": "mg",
"strength": "22.5 mg",
"atc_label": "triptoreliini",
"ma_number": "43113",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL62179",
"authorised_at": "2024-02-21"
}See everything about triptorelin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.